Australia's most trusted
source of pharma news
Posted 28 November 2025 AM
Bayer and Sandoz have come to an agreement over a potential launch of a biosimilar referencing blockbuster eye drug Eylea, ending the court case just before a ruling was given on an appeal by Bayer.
"We can confirm that a patent dispute lodged by Bayer and Regeneron against Sandoz in Australia has been settled out of court," Bayer told Pharma in Focus. "The dispute relates to Sandoz' 2mg aflibercept biosimilar. The terms of the settlement are confidential, therefore Bayer can offer no further comment at this time."

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.